Northbrook, IL 60062 -- (SBWIRE) -- 07/07/2023 -- Cell based Assays Market in terms of revenue was estimated to be worth $18.9 billion in 2023 and is poised to reach $28.2 billion by 2028, growing at a CAGR of 8.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global cell-based assays market is expected to grow at a CAGR of 8.4% during the forecast period. The market for cell-based assays is experiencing significant growth primarily due to the increasing demand for drug discovery and development, as well as the rising adoption of cell-based assays in this process. Government support and funding for cell-based research initiatives are further contributing to this growth. Additionally, efforts by regulatory authorities, such as the FDA, to reduce reliance on animal-based studies are driving the adoption of cell-based assays.

The cell-based assays industry is poised for significant advancements in the near future. With ongoing advancements in cell culture techniques, automation, and high-throughput screening technologies, cell-based assays will play a crucial role in drug discovery, toxicity testing, and personalized medicine. The industry will witness the development of more physiologically relevant and complex 3D cell models, allowing for better prediction of drug efficacy and safety. Integration of innovative technologies such as organ-on-a-chip systems and microfluidics will further enhance the capabilities of cell-based assays, enabling more accurate and reliable testing. Moreover, the industry will focus on leveraging artificial intelligence and machine learning algorithms to analyze complex data generated from these assays, facilitating faster and more precise decision-making in drug development. Overall, the near future of the cell-based assays industry holds great promise, with advancements in technology and techniques paving the way for improved drug discovery processes and personalized approaches to healthcare.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269

Browse in-depth TOC on "Cell based Assays Market"

338 - Tables
43 - Figures
344 – Pages

The instruments and software segment accounted for the second largest share, by product and service in the cell-based assays market in 2022.

These sophisticated instruments enable researchers to automate and streamline various aspects of cell-based assays, enhancing efficiency, accuracy, and throughput. Additionally, powerful software platforms provide advanced data analysis, visualization, and integration capabilities, enabling researchers to derive valuable insights from their experiments. The integration of cutting-edge instruments and software solutions into cell-based assays research workflows is revolutionizing the field and propelling the market forward.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the cell-based assays market in 2022.

The pharmaceutical & biopharmaceutical companies dominated the market in 2022. Pharmaceutical & biopharmaceutical companies are the largest end users of cell-based assays. The demand for cell-based assays in this end-user segment is driven by the growth in the number of R&D activities for the development of new pharma and biotech drugs and therapies coupled with the adoption of cell-based assays in these companies.

The North America region catered the largest share of the cell-based assays market in 2022.

North America has emerged as the dominant region in the cell-based assays market. The region's leadership can be attributed to several factors, including a robust pharmaceutical and biotechnology industry, extensive research and development activities, and a favorable regulatory environment. Furthermore, the presence of key market players, advanced healthcare infrastructure, and significant investments in drug discovery and development contribute to North America's strong market position. The region's emphasis on technological advancements and the adoption of innovative approaches in cell-based assays further solidifies its dominance in the market.

Get 10% Free Customization on this Report:https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=119917269

Cell based Assays Market Dynamics:

Drivers:

1. Growing preference for cell-based assays in drug discovery
2. Increasing funding for cell-based research
3. Growth in the number of drug discovery activities

Restraints:

1. High cost of instruments and restrictions on reagent use
2. Lack of infrastructure for cell-based research in emerging economies

Opportunities:

1. Emerging economies
2. Growing risk of pandemics and communicable diseases
3. Application of novel cell-based assays in cancer research

Key Market Players:

Key players in the cell-based assays market include Danaher Corporation (US), Thermo Fisher Scientific (US), Merck (Germany), Becton, Dickinson and Company (US), Lonza (Switzerland), PerkinElmer (US), Charles River Laboratories (US), Eurofins Scientific (France), Enzo Biochem (US), Carna Biosciences (Japan), Cell Biolabs (US), Promega Corporation (US), Cell Signaling Technology (US), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), Pestka Biomedical Laboratories (US), InvivoGen (US), CA3 Biosciences (US), BPS Bioscience (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), and JRS Pharma (Germany).

Report Link: Cell based Assays Market

Recent Developments:

- In December 2021, Thermo Fisher Scientific acquired PPD to enhance its clinical research services for the biopharma and biotech industries

- In March 2020, Danaher acquired General Electric's Life Sciences Division (and renamed it Cytiva) to enhance its Life Sciences products and services portfolio.

Cell based Assays Market Advantages:

- Physiological Relevance: Cell-based assays utilize living cells, providing a more physiologically relevant environment compared to traditional biochemical assays. This allows for the assessment of drug efficacy, toxicity, and interactions in a more accurate and predictive manner, leading to better understanding of biological mechanisms and improved translatability to human responses.

- High Sensitivity and Specificity: Cell-based assays offer high sensitivity and specificity in detecting and measuring biological responses. They can detect subtle changes in cellular functions, such as cell viability, proliferation, apoptosis, and signaling pathways, enabling the identification of potential drug candidates or toxic compounds with greater precision.

- Versatility and Flexibility: Cell-based assays can be designed and adapted to various research needs and objectives. They can be customized to assess specific targets, diseases, or pathways, allowing researchers to address diverse scientific questions and develop tailored solutions. This versatility makes cell-based assays applicable across different therapeutic areas and research fields.

- Predictive Value: By utilizing human or relevant animal cell lines, cell-based assays offer better predictability of drug responses compared to non-cell-based models. They can provide insights into drug efficacy, safety, and potential side effects, helping researchers and pharmaceutical companies make more informed decisions during drug development stages, leading to improved success rates and reduced costs.

- High-Throughput Screening Capabilities: With advancements in automation and robotics, cell-based assays have become amenable to high-throughput screening. This enables the rapid testing of large compound libraries, accelerating the drug discovery process and increasing the chances of identifying potential lead compounds.

- Reduction of Animal Testing: Cell-based assays provide a valuable alternative to animal testing in drug development and toxicology studies. They allow for preliminary evaluation of drug candidates and toxicity profiles, reducing the reliance on animal models and contributing to the ethical treatment of animals in research.
- Integration with Advanced Technologies: Cell-based assays can be integrated with other advanced technologies, such as imaging systems, microfluidics, and gene editing tools like CRISPR-Cas9. This integration allows for real-time monitoring of cellular responses, enhanced data collection, and manipulation of cellular systems, expanding the capabilities and applications of cell-based assays.

- Cost-Effectiveness: Cell-based assays can offer cost savings compared to in vivo animal models and provide faster results. By reducing the need for expensive animal studies and streamlining the drug discovery process, cell-based assays contribute to cost-effective research and development.

Overall, the advantages of cell-based assays include their physiological relevance, sensitivity, versatility, predictive value, high-throughput screening capabilities, reduction of animal testing, integration with advanced technologies, and cost-effectiveness. These advantages make cell-based assays an indispensable tool in pharmaceutical research, toxicology screening, and the development of novel therapeutic interventions.